Rendiatech
Real-time Renal Diagnostics
Company Overview
Snapshot
Founded in June 2009 by Avi Kleiman and Mor Grinstein, Rendiatech operates with 1–10 employees. The company has raised a total of $29.83M across 5 funding rounds and secured a grant from the Israel Innovation Authority in May 2019. In August 2025, Rendiatech was acquired by Nuwellis.
Business overview
Rendiatech is a medical device company focused on real-time renal diagnostics. Its core product, Clarity RMS, is a critical care monitoring system designed to facilitate early detection of changes in renal function and acute kidney injury (AKI) risk, as well as treatment monitoring. This system provides continuous, automatic urine flow monitoring, aiming to improve patient care and ICU economics. The company serves medical centers globally, including in the U.S., Europe, and Israel, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices, Diagnostics Devices, and Medical Monitors.
Strategic signal
In August 2025, Nuwellis signed a Letter of Intent to explore the acquisition of Rendiatech. This development signals a strategic consolidation within the medical device industry, indicating a potential expansion of Nuwellis's critical care offerings and validating Rendiatech's technology and market position in real-time renal diagnostics.
Company Intelligence Q&A
- What is Rendiatech's primary product?
- Rendiatech's primary product is Clarity RMS, a critical care monitoring system that provides continuous, automatic monitoring of urine flow for early detection of changes in renal function and acute kidney injury (AKI) risk.
- When was Rendiatech acquired?
- Rendiatech was acquired by Nuwellis in August 2025.
- When did Rendiatech raise its Series A funding round?
- In November 2021, Rendiatech raised a Series A funding round, with BlueRed Partners participating.
- Has Rendiatech's Clarity RMS system received regulatory clearances?
- Yes, the Clarity RMS system has received FDA clearance and CE certification, enabling its installation in leading medical centers across the U.S., Europe, and Israel.